OFEV to be Tested in Scleroderma Patients with Interstitial Lung Disease

admin avatar

by admin |

Share this article:

Share article via email

Boehringer Ingelheim recently announced the enrollment of the first patient in the Phase 3 clinical trial SENSCIS (Safety and Efficacy of Nintedanib in Systemic SClerosIS) evaluating the safety and efficacy of the company’s product nintedanib (OFEV) in patients with systemic sclerosis and interstitial lung disease.

Watch video above to learn more about OFEV.

Read the full article here: http://bit.ly/1In9XB9